Macromolecular Anticancer Therapeutics

0350338 - MBÚ 2011 RIV US eng M - Monography Chapter
Říhová, Blanka - Hovorka, Ondřej - Kovář, Lubomír - Kovář, Marek - Mrkvan, Tomáš - Šírová, Milada - Šubr, Vladimír - Ulbrich, Karel
HPMA – Anticancer Drug Conjugates.
Macromolecular Anticancer Therapeutics. New York: Springer, 2010 - (Reddy, L.; Couvreur, P.), s. 87-132. ISBN 978-1-4419-0506-2
R&D Projects: GA AV ČR KAN200200651; GA AV ČR IAAX00500803; GA MŠMT 1M0505
Institutional research plan: CEZ:AV0Z50200510; CEZ:AV0Z40500505
Keywords : hpma * doxorubicin * cytotoxicity
Subject RIV: EC - Immunology

Homopolymer poly(HPMA) was originally developed as a blood expander “Duxon.” Later on, linear Nondegradable HPMA copolymer of a molecular weight 25kDa was used as the backbone to which drugs, mostly doxorubicin, were attached through different side chains and different covalent bonds. Non-targeted and targeted polymer–drug derivatives based on HPMA have both cytostatic and immunostimulating activity. Their impressive anti-tumor effects most likely result from the combination of strong direct cytotoxicity and a systemic anticancer resistance regularly induced during the treatment
Permanent Link: http://hdl.handle.net/11104/0190365